Real-life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients

Authors :: Kos, Renate
Neerincx, A.H.
Fenn, Dominic W.
Brinkman, Paul
Lub, Rianne
Vonk, Steffie E.M.
Roukema, J.
Reijers, M.H.
Haarman, Eric G.
Maitland-van der Zee, Anke H.
Kos, Renate
Neerincx, A.H.
Fenn, Dominic W.
Brinkman, Paul
Lub, Rianne
Vonk, Steffie E.M.
Roukema, J.
Reijers, M.H.
Haarman, Eric G.
Maitland-van der Zee, Anke H.
Source :: Pharmacology Research & Perspectives; 2052-1707; 6; 10; e01015; ~Pharmacology Research & Perspectives~~~~~2052-1707~6~10~~e01015
Publication Year :: 2022
Abstract: Item does not contain fulltext

Database :: OAIster
Journal :: Pharmacology Research & Perspectives; 2052-1707; 6; 10; e01015; ~Pharmacology Research & Perspectives~~~~~2052-1707~6~10~~e01015
Publication Type :: Electronic Resource
Accession number :: edsoai.on1366916434
Document Type :: Electronic Resource

Tools